{"id":9863,"date":"2025-11-04T06:18:57","date_gmt":"2025-11-04T12:18:57","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9863"},"modified":"2025-11-04T10:07:10","modified_gmt":"2025-11-04T16:07:10","slug":"nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306e\u7b2c1\/2a\u76f8\u8ffd\u8de1\u8abf\u67fb\u306b\u304a\u3051\u308b5\u5e74\u9593\u306e\u5b89\u5168\u6027\u7d50\u679c\u3092\u767a\u8868"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"9863\" class=\"elementor elementor-9863\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span class=\"legendSpanClass\">\u30c0\u30e9\u30b9<\/span>,\u00a0<span class=\"legendSpanClass\">2025\u5e7411\u67084\u65e5<\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u00a0\u672c\u65e5\u3001\u540c\u793e\u306e\u9577\u671f\u5b89\u5168\u6027\u306b\u95a2\u3059\u308b\u826f\u597d\u306a\u7d50\u679c\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u00a0<b>\u4f38\u3070\u3059<\/b>\u00a0\u672c\u7814\u7a76\u306f\u3001\u4ee5\u524d\u306e\u7b2c1\/2a\u76f8\u81e8\u5e8a\u8a66\u9a13\u3067MCO-010\u306e\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u30921\u56de\u53d7\u3051\u305f\u53c2\u52a0\u8005\u30925\u5e74\u9593\u8ffd\u8de1\u8abf\u67fb\u3057\u305f\u3082\u306e\u3067\u3042\u308b\u3002.\u00a0<\/p><p>EXTEND\u8a66\u9a13\u3067\u306f\u3001\u9032\u884c\u6027\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u800510\u540d\u3092\u5bfe\u8c61\u306b\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u72ec\u81ea\u306e\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3092\u7528\u3044\u3066\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3067\u3042\u308bMCO-010\u3092\u4ee5\u524d\u306b\u6295\u4e0e\u3057\u305f\u75c7\u4f8b\u3092\u8ffd\u8de1\u8abf\u67fb\u3057\u305f\u3002.<\/p><p>EXTEND\u306f\u3001\u00a0<b>MCO-010\u306e\u785d\u5b50\u4f53\u5185\u5358\u56de\u6ce8\u5c04\u306f\u30015\u5e74\u9593\u306b\u308f\u305f\u308a\u5b89\u5168\u3067\u5fcd\u5bb9\u6027\u304c\u9ad8\u3044\u3002<\/b>, \u91cd\u5927\u306a\u526f\u4f5c\u7528\u3084\u65b0\u305f\u306a\u5b89\u5168\u6027\u306e\u5146\u5019\u306f\u306a\u304f\u3001\u00a0<b>\u540c\u30585\u5e74\u9593\u3067\u751f\u6d3b\u306e\u8cea\u306e\u6539\u5584\u304c\u898b\u3089\u308c\u305f<\/b>.<\/p><p><b>\u9577\u671f\u306b\u308f\u305f\u308b\u512a\u308c\u305f\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb<\/b><\/p><p>5\u5e74\u9593\u306b\u308f\u305f\u308a\u3001\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u306f\u7b2c1\/2a\u76f8\u8a66\u9a13\u3068\u9577\u671f\u8ffd\u8de1\u671f\u9593\u306e\u9593\u3067\u4e00\u8cab\u3057\u3066\u304a\u308a\u3001\u7ba1\u7406\u53ef\u80fd\u306a\u4e00\u904e\u6027\u306e\u708e\u75c7\u3001\u6295\u4e0e\u4e2d\u6b62\u4f8b\u306a\u3057\u3001\u65b0\u305f\u306a\u5b89\u5168\u6027\u30b7\u30b0\u30ca\u30eb\u306a\u3057\u3068\u3044\u3046\u7d50\u679c\u3067\u3042\u3063\u305f\u3002.<\/p><p>\u201c\u300c\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001MCO-010\u306e\u512a\u308c\u305f\u9577\u671f\u7684\u306a\u5b89\u5168\u6027\u3068\u5fcd\u5bb9\u6027\u3092\u793a\u3057\u3066\u304a\u308a\u30011\u56de\u306e\u6ce8\u5c04\u304b\u30895\u5e74\u5f8c\u3067\u3082\u305d\u306e\u52b9\u679c\u304c\u6301\u7d9a\u3059\u308b\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/who-we-are\/samarendra-mohanty\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3\u535a\u58eb\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u793e\u9577\u517c\u6700\u9ad8\u79d1\u5b66\u8cac\u4efb\u8005<\/a>. \u300c\u91cd\u5927\u306a\u5b89\u5168\u6027\u306e\u5146\u5019\u304c\u898b\u3089\u308c\u305a\u3001\u88ab\u9a13\u8005\u306e\u7d99\u7d9a\u7387\u3082\u9ad8\u3044\u3053\u3068\u304b\u3089\u3001MCO-010\u306f\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306b\u5bfe\u3059\u308b\u3001\u6301\u7d9a\u6027\u306e\u3042\u308b\u975e\u4fb5\u8972\u7684\u306a\u6cbb\u7642\u6cd5\u3068\u3057\u3066\u6709\u671b\u3067\u3042\u308b\u3053\u3068\u304c\u793a\u5506\u3055\u308c\u308b\u3002\u300d\u201c<\/p><p><b>\u6301\u7d9a\u7684\u306a\u6709\u52b9\u6027<\/b><\/p><p>\u521d\u671f\u8a66\u9a13\u3067\u306f\u3001MCO-010\u306e\u9ad8\u7528\u91cf\u3092\u6295\u4e0e\u3055\u308c\u305f\u53c2\u52a0\u8005\u306f\u30011\u5e74\u5f8c\u306b\u8996\u529b\u306e\u7d71\u8a08\u7684\u306b\u6709\u610f\u306a\u6539\u5584\u3092\u793a\u3057\u305f\u3002\u53c2\u52a0\u8005\u306f\u5f15\u304d\u7d9a\u304d\u3001\u00a0<b>\u8996\u899a\u95a2\u9023\u306e\u751f\u6d3b\u306e\u8cea\u304c\u5b89\u5b9a\u307e\u305f\u306f\u6539\u5584\u3057\u3066\u3044\u308b<\/b>\u00a0\u3053\u306e5\u5e74\u9593\u3067\u3001\u7279\u306b\u9060\u9694\u6d3b\u52d5\u3084\u8996\u899a\u306b\u7279\u5316\u3057\u305f\u81ea\u7acb\u5ea6\u8a55\u4fa1\u306b\u304a\u3044\u3066\u9855\u8457\u306a\u6539\u5584\u304c\u898b\u3089\u308c\u305f\u3002.\u00a0<\/p><p>\u3053\u306e\u30c7\u30fc\u30bf\u306f\u6700\u8fd1\u767a\u8868\u3055\u308c\u305f\u00a0<a href=\"https:\/\/vrsi.in\/wp-content\/uploads\/2025\/10\/Scientific-Program-VRSI-2025.pdf\" target=\"_blank\" rel=\"nofollow noopener\">34<sup>\u756a\u76ee<\/sup>\u00a0\u785d\u5b50\u4f53\u7db2\u819c\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a \u2013 \u30a4\u30f3\u30c9<\/a>.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u3001\u75be\u60a3\u306e\u7a2e\u985e\u3092\u554f\u308f\u305a\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u4e3b\u529b\u88fd\u54c1\u3067\u3042\u308bMCO-010\u306e\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u3092FDA\u306b\u6bb5\u968e\u7684\u306b\u63d0\u51fa\u3057\u59cb\u3081\u307e\u3057\u305f\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001MCO-010\u304c\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u306e\u6cbb\u7642\u306b\u3082\u6709\u671b\u306a\u7d50\u679c\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u3068\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001\u3055\u3089\u306b\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u3067\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u975e\u75c7\u5019\u6027\u304a\u3088\u3073\u75c7\u5019\u6027\u306e\u687f\u4f53\u30fb\u9310\u4f53\u512a\u4f4d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3001\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3092\u5bfe\u8c61\u3068\u3057\u305fEMA\u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306b\u5bfe\u3059\u308bMCO\u306e\u7b2c2\u76f8\u81e8\u5e8a\u8a66\u9a13\u306f\u30012025\u5e74\u672b\u307e\u3067\u306b\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002.<\/p><p><b>\u63a5\u89e6\uff1a<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Nov. 4, 2025\u00a0 \u2014 Nanoscope Therapeutics Inc.\u00a0announced today positive long-term safety results from its\u00a0EXTEND\u00a0study, a five-year follow-up of participants who received a single intravitreal injection of MCO-010 in an earlier Phase 1\/2a trial.\u00a0 The EXTEND study followed ten participants with advanced retinitis pigmentosa (RP) who had previously received MCO-010, an optogenetic therapy designed to restore vision using Nanoscope\u2019s proprietary Multi-Characteristic Opsin (MCO) platform. EXTEND confirmed that\u00a0a single intravitreal injection of MCO-010 is safe and well-tolerated over five years, with no serious adverse effects or new safety signals, alongside\u00a0quality-of-life improvements seen over the same five years. Strong Long-Term Safety Profile Over five years, the safety profile remained consistent between the Phase [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9863","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T12:18:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T16:07:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\\\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa\",\"datePublished\":\"2025-11-04T12:18:57+00:00\",\"dateModified\":\"2025-11-04T16:07:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\"},\"wordCount\":408,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\\\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-11-04T12:18:57+00:00\",\"dateModified\":\"2025-11-04T16:07:10+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/11\\\/04\\\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\\\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306e\u7b2c1\/2a\u76f8\u8ffd\u8de1\u8abf\u67fb\u306b\u304a\u3051\u308b5\u5e74\u9593\u306e\u5b89\u5168\u6027\u7d50\u679c\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-11-04T12:18:57+00:00","article_modified_time":"2025-11-04T16:07:10+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa","datePublished":"2025-11-04T12:18:57+00:00","dateModified":"2025-11-04T16:07:10+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/"},"wordCount":408,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308bMCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u306e\u7b2c1\/2a\u76f8\u8ffd\u8de1\u8abf\u67fb\u306b\u304a\u3051\u308b5\u5e74\u9593\u306e\u5b89\u5168\u6027\u7d50\u679c\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-11-04T12:18:57+00:00","dateModified":"2025-11-04T16:07:10+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/11\/04\/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-1-2a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1\/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=9863"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9863\/revisions"}],"predecessor-version":[{"id":9870,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9863\/revisions\/9870"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=9863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=9863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=9863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}